AxoGen, Inc (NASDAQ:AXGN) was the target of some unusual options trading on Wednesday. Stock investors acquired 2,749 put options on the company. This is an increase of 2,290% compared to the average volume of 115 put options.
Several hedge funds have recently modified their holdings of AXGN. Advisor Group Inc. grew its holdings in AxoGen by 130.3% in the 1st quarter. Advisor Group Inc. now owns 1,368 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 774 shares during the last quarter. Quantamental Technologies LLC grew its holdings in AxoGen by 108.3% in the 1st quarter. Quantamental Technologies LLC now owns 1,431 shares of the medical equipment provider’s stock valued at $30,000 after buying an additional 744 shares during the last quarter. Oppenheimer Asset Management Inc. acquired a new stake in AxoGen in the 4th quarter valued at approximately $77,000. NumerixS Investment Technologies Inc acquired a new stake in AxoGen in the 4th quarter valued at approximately $131,000. Finally, BNP Paribas Arbitrage SA grew its holdings in AxoGen by 8,717.5% in the 1st quarter. BNP Paribas Arbitrage SA now owns 7,054 shares of the medical equipment provider’s stock valued at $149,000 after buying an additional 6,974 shares during the last quarter. 89.10% of the stock is currently owned by institutional investors and hedge funds.
Shares of AXGN stock opened at $23.92 on Friday. AxoGen has a twelve month low of $14.13 and a twelve month high of $56.85. The company has a market capitalization of $931.56 million, a P/E ratio of -44.30 and a beta of 0.20.
A number of brokerages recently weighed in on AXGN. Cantor Fitzgerald set a $26.00 price objective on AxoGen and gave the company a “buy” rating in a research note on Monday, April 22nd. BidaskClub raised AxoGen from a “hold” rating to a “buy” rating in a research note on Saturday, May 4th. BTIG Research raised AxoGen from a “neutral” rating to a “buy” rating and set a $28.00 price objective on the stock in a research note on Monday, March 25th. Finally, ValuEngine raised AxoGen from a “hold” rating to a “buy” rating in a research note on Wednesday, May 1st. Five research analysts have rated the stock with a buy rating, AxoGen presently has a consensus rating of “Buy” and a consensus target price of $37.67.
ILLEGAL ACTIVITY WARNING: This piece of content was reported by Dakota Financial News and is the property of of Dakota Financial News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://dakotafinancialnews.com/2019/05/10/axogen-target-of-unusually-high-options-trading-axgn.html.
AxoGen, Inc develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Read More: Why is the conference call important?
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.